Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=939 Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.89; 2.76; 2.37; 1.54 months — p=0.756
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=51 Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Median Progression Free Survival — 7.8 Months
Phase 2 N=23 Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control(DC) Rate of Gefitinib Retreatment Per RECIST Criteria (V1.1) and Assessed by CT — 65.2 percentage of participant with DC
Phase 2 N=63 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate Defined as Complete or Partial Response as Assessed by RECIST Version 1.0 Criteria. — 38.1; 0 percentage of patients
Phase 2 N=80 Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate — 65; 50 percentage of participants
Phase 2 N=86 Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate — 18; 34; 28 percentage of participants
Phase 2 N=3 Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.35; 14.3 months
Phase 2 N=342 Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Lung Cancer
Primary: Number of Patients Maintaining Stable Disease or Objective Response 2 Months After Randomization — 0; 0; 27; 7 participants — p=0.005
Phase 2 N=66 E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Objective Response Rate (CR or PR) According to RECIST Criteria — 5 percentage of patients responding
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Phase 2 N=303 A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level — 42.86; 47.69…
Phase 2 N=82 Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Rovalpituzumab Tesirine — 0.4 mg/kg
Phase 2 N=37 AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Rate of Disease Control (Freedom From Disease Progression) — 4 participants
Phase 3 N=583 Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC)
Primary: Overall Survival (OS) Time — 16.1; 15.5 months
Phase 2 N=52 Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer
Primary: Time to Progression — 3.12; 1.64 months
Phase 2 N=75 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Lung Cancer
Primary: Overall Survival at 12 Months — 57 percentage of participants
Phase 2 N=30 Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Phase 2 N=4 TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) — 0 Participants
Phase 2 N=153 A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
Phase 2 N=36 Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cetuximab — 750 mg/m^2 every 21 days
Phase 2 N=280 A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 5.6; 7.2; 5.4; 5.6 months — p=0.1318
Phase 2 N=166 Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
Phase 2 N=101 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: 18 Month Survival — 58; 54 percentage of participants
Phase 2 N=9 Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I) — 150 mg daily
Phase 2 N=112 Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
Non-Small Cell Lung Cancer
Primary: Disease-free Survival — NA; 55.1 months
Phase 2 N=22 Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Number of Subjects With Progression Free Survival — 6 Participants
Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants